RecruitingPhase 2NCT03779854
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Studying Acute biphenotypic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Marie Bleakley, MDFred Hutch/University of Washington Cancer Consortium
- Intervention
- Total-Body Irradiation(radiation)
- Enrollment
- 68 enrolled
- Eligibility
- 26 years · All sexes
- Timeline
- 2019 – 2027
Study locations (10)
- Children's Hospital of Los Angeles, Los Angeles, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- Dana Farber / Boston Children's Hospital, Boston, Massachusetts, United States
- UH Rainbow Babies and Children's Hospital (University Hospitals Cleveland Medical Center), Cleveland, Ohio, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03779854 on ClinicalTrials.govOther trials for Acute biphenotypic leukemia
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07517510HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).Guangdong Second Provincial General Hospital
- RECRUITINGPHASE1, PHASE2NCT07356154A Study of Revumenib and Mezigdomide in People With LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT07537738Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid LeukemiaPeking University People's Hospital
- RECRUITINGPHASE1, PHASE2NCT05589896A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesOssium Health, Inc.
- RECRUITINGNANCT05794880MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingMedical College of Wisconsin
- ACTIVE NOT RECRUITINGPHASE2NCT03399773Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic SyndromesFred Hutchinson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04797767Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsUniversity of Washington
- ACTIVE NOT RECRUITINGPHASE2NCT04975919Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center